Home / Market News / $ABBV
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Health Canada Approves AbbVie's Skyrizi for Pediatric Plaque Psoriasis

Oct 22, 2026, 2:02 AM UTC · Primary ticker $ABBV

AbbVie's Skyrizi has received Health Canada approval for pediatric plaque psoriasis, expanding its market reach for this IL-23 inhibitor. This provides a new treatment option for young patients and strengthens AbbVie's immunology franchise, though the immediate financial impact is likely moderate given the specific patient population.

AbbVie announced that Health Canada has approved its drug Skyrizi (risankizumab) for pediatric patients aged 6 to under 18 with moderate-to-severe plaque psoriasis. This approval is based on positive Phase III data, demonstrating high rates of skin clearance. This is a positive development for AbbVie as it expands the addressable market for one of its key immunology assets, Skyrizi, and reinforces its leadership in the IL-23 inhibitor space. While the pediatric market for psoriasis is smaller than the adult market, it represents a new revenue stream and strengthens the drug's overall franchise value. For traders, this is a long-term positive for ABBV, indicating continued pipeline success and market expansion, but the short-term stock impact is likely modest given the niche patient population.

$ABBV positive Expanded market approval for key drug
$JNJ neutral Competitor in immunology market
$LLY neutral Competitor in immunology market
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.